Ziresovir's Phase III results mark a significant milestone, representing the first clinical validation of an antiviral's ...

Although we can’t control what others chose to do about handwashing and social distancing, we can decide to protect our ...

The Ministry of Public Health (MoPH) has advised the public, especially the vulnerable to take the Respiratory Syncytial ...

Major study shows that adults with respiratory syncytial virus-associated acute respiratory infection face a 2.7-fold higher ...

Common symptoms of pneumonia include a persistent cough, difficulty breathing, high fever, chest pain, body aches, extreme ...

While most infants affected by RSV experience mild symptoms and do not require hospitalisation, certain groups are at a higher risk for severe illness. Infants under six months are particularly ...

RSV is a common contagious virus characterised by several mild, cold-like symptoms. Although most people can recover within a week or two, the virus can cause severe illness in certain groups, ...

Learn more about similarities and differences in symptoms, prevention, and other key aspects between RSV and coronavirus. You can get RSV at any age, but it's most common in infants and children ...

GlaxoSmithKline (NYSE:GSK) and Pfizer (NYSE:PFE) have agreed to dismiss a U.S. patent lawsuit over Pfizers RSV vaccine, ...

Pfizer’s RSV vaccine Abrysvo receives European approval to help protect adults aged 18-59 against RSV lower respiratory tract disease: New York Wednesday, April 2, 2025, 09:00 H ...

The Royal Australian College of GPs (RACGP) has thrown its support behind Victoria's infant RSV vaccine program. Respiratory syncytial virus, or RSV ...